Background
The conventional standard treatment for ovarian cancer is not very effective, and the disease is fatal for women. Cancer Stem Cells (CSCs) that express CD44+/CD24- can contribute to chemoresistance and a poor prognosis. We seek to investigate the expression of CSCs (CD44+/CD24-) in ovarian cancer and their predictive significance.
Methods
The ambispective cohort was performed on 64 patients (32 patients in each group) at four hospitals (Cipto Mangunkusumo, Tarakan, Fatmawati, and Dharmais Hospital). Debulking surgery was performed on the patients, followed by histopathological analysis. The patients had six rounds of chemotherapy and were under monitoring for six months. The therapeutic responses were evaluated using the RECIST criteria (Response Criteria in Solid Tumors) and categorized as chemoresistant or chemosensitive. Using immunohistochemistry, we directly assess the CSCs from ovarian cancer tissue and using flow cytometry to assess the CSCs from the blood.
Results
High CSCs expression and ovarian cancer chemoresistance were significantly related in both trials (p 0.05). A better outcome was obtained using CD44+/CD24- immunohistochemistry.
Conclusions
We conclude that there is a substantial association between high CSCs expression and chemoresistance in ovarian cancer and that CSCs immunohistochemistry has a higher predictive value.
mAb showed stronger anti-tumor effect in HFD mouse than that in ND mouse (57.2% and 26,6%, respectively). Metabolomic analysis using HFD and ND mouse serum detected 210 metabolites and The Human Metabolome Database provided comprehensive information of 83 metabolites. Principal component analysis and cluster analysis using these metabolites showed obviously different metabolic properties between ND and HFD mouse. Partial Least Squares-Discriminant Analysis showed significantly high score of lipid metabolites in HFD mouse including a-Tocopherol and cholesterol. Conclusions Metabolomics showed the activation of lipid metabolism in HFD mouse and suggested that LSR contributed tumor growth via lipid metabolism.
Objective: Ovarian cancer is the 8th deadliest women’s cancer in the world. Almost all patients experienced chemoresistance, recurrence, and poor prognosis after cytoreductive surgery followed by platinum-based chemotherapy. Chemoresistant cancer cells have characteristic expressions of RAD6, DDB2, and cancer stem cell proteins (CSCs, CD44+/CD24-). Increased expression of CD44+/CD24-, RAD6, and decreased DDB2 are believed to be associated with chemoresistance, recurrence, and poor prognosis of the disease. The study objective is to analyse the correlation between expression of RAD6, DDB2, CD44+/CD24- with ovarian cancer chemoresistance.Methods: This study is a prospective cohort of 32 people in each group at the Obstetrics-gynecology and pathology Department of Cipto Mangunkusumo, Tarakan, Dharmais, and Fatmawati Hospital. All suspected ovarian cancer patients will undergo cytoreductive debulking and histopathological examination. Chemotherapy will be given for six series followed by six months of observation. We determine therapy response with the RECIST Criteria (Response Criteria in Solid Tumors) then classify it into chemoresistant or chemosensitive groups. The patient will perform Flow cytometry blood tests to examine the expression of RAD6 and DDB2 and CD44+/CD24-. Results: There was a significant relationship between increased levels of CD44+/CD24-, RAD6, and reduced DDB2 protein (p<0,05) with chemoresistance of ovarian cancer. Logistic regression test showed that the results of CD44+/CD24‑ was the best marker. Conclusion: These results indicate that CD44+/CD24-, RAD6, and DDB2 expressions are significantly associated with ovarian cancer chemoresistance, and CD44+/CD24- is the primary marker to predict ovarian cancer chemoresistance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.